Skip to main content

Atara Biotherapeutics, Inc.

corporate_fare Company Profile

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed ATRA - Latest Insights

ATRA
Mar 25, 2026, 5:07 PM EDT
Filing Type: 424B3
Importance Score:
8
ATRA
Mar 17, 2026, 4:17 PM EDT
Filing Type: S-3
Importance Score:
8
ATRA
Mar 16, 2026, 4:20 PM EDT
Filing Type: 424B5
Importance Score:
8
ATRA
Mar 16, 2026, 4:15 PM EDT
Filing Type: 10-K
Importance Score:
9
ATRA
Mar 16, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
ATRA
Mar 12, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
7
ATRA
Mar 03, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
7
ATRA
Feb 23, 2026, 8:29 AM EST
Filing Type: 8-K
Importance Score:
8
ATRA
Jan 14, 2026, 9:20 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
ATRA
Jan 14, 2026, 9:16 PM EST
Filing Type: 4
Importance Score:
8
ATRA
Jan 12, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
9
ATRA
Jan 02, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7